What NeoVista does

NeoVista Inc. is a privately held U.S. corporation headquartered in Newark and historically positioned as a medical technology developer targeting wet age-related macular degeneration (wet AMD), a leading cause of irreversible vision loss in older adults. According to firmographic records, the company was founded in 2002 and historically operated with 11–50 employees, raising approximately $155 million across 11 disclosed funding rounds from 2003 through 2012. Capital was sourced from a concentrated syndicate of healthcare-focused venture and growth investors — Accuitive Medical Ventures, Essex Woodlands Healthcare Partners, MPM Capital, SV Health Investors, The Carlyle Group, Versant Ventures — supplemented by structured financing from GE Capital and Oxford Finance LLC. Essex Woodlands Healthcare Partners served as lead investor on multiple later-stage rounds. The company's historical go-to-market depended on regulated medical device development for the ophthalmology channel, with leadership comprising co-founder Charles E. Larsen and executive chairman Andy Corley.

The current operating posture is materially different from the historical record. The website at neovistainc.com today presents a free, consumer-facing eye health content platform offering three browser-based interactive tools — an Online Snellen Chart with credit-card calibration for visual acuity self-testing, an SVG-based Ishihara-style color blindness screening test, and a screen time calculator that estimates digital eye strain risk — supported by a library of 16+ articles on topics including computer vision syndrome, blue light filtering, the 20-20-20 rule, dry eye management, monitor ergonomics, eye exercises, supplements, and pediatric screen time. All tools and articles are free, require no login, and run entirely client-side. There is no disclosed pricing model, no subscription tier, no advertising inventory, no e-commerce, no API, no mobile app, and no social media presence. The operation is described as a bootstrapped, founder-owned personal project with no institutional funding, no parent company, no subsidiaries, and no documented partnerships.

The disconnect between the firmographic record (medical device developer, 11–50 employees, $155M+ raised) and the website's current state (one-person free content site) is significant. There is no evidence of active medical device commercialization, no current FDA filings or regulatory milestones, and no commercial transaction layer on the website. The most plausible reading is that the original medical device business has been wound down, divested, or otherwise ceased active operations after the 2012 funding events, and the domain is either repurposed or retained by an unrelated operator. As an investment subject, NeoVista presents as either a dormant/wound-down medical device entity with residual IP and investor history, or an unrelated bootstrapped content site, with material diligence required to clarify which entity the investor is actually acquiring exposure to.

Name

NeoVista

Legal name

NeoVista Inc.

Website

https://neovistainc.com

Company type

Private

Founded year

2026

Operating status

Operating

Headcount range

11–50 employees

Short description

NeoVista Inc. is a privately held U.S. medical technology company historically focused on wet age-related macular degeneration treatment, having raised approximately $155 million across 11 funding rounds from 2003 to 2012; the entity's current website now operates a free consumer eye health content and screening-tools platform targeting screen workers.

Ownership category

akta.pro rank

Product category

Digital Health Content

NAICS

Optical Goods Retailers (45613), Other Scientific and Technical Consulting Services (54169)

SIC

Ophthalmic Goods (3851)

akta.pro primary industry

Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography) (HLAHAJAB)

akta.pro secondary industry

Visual Field & Functional Vision Testing (Perimetry, ERG/VEP, Contrast Sensitivity) (HLAHAJAC)

Keywords

• Vision health tools
• Digital eye strain
• Online vision screening
• Screen time tracking
• Eye care content

Headquarters

HQ city

Newark

HQ country

United States

HQ region

North America

Markets served

GTM type

B2C

Offering type

Digital Commerce or Content

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. Content/Site Revenue: Revenue model not explicitly disclosed. The site offers all tools and articles for free. No subscription, advertising, or e-commerce elements are visible in the source content.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

NeoVista operates a free, science-based online vision health platform at neovistainc.com that delivers interactive browser-based screening tools (Online Snellen Chart, Color Blind Test, Screen Time Calculator) alongside a library of research-cited articles on digital eye strain, blue light, dry eye, monitor ergonomics, eye drops, supplements, and corrective lenses for heavy screen users. The offering is entirely free, with no subscriptions, paywalls, or downloads, positioned as a personal editorial project for office workers and parents concerned about screen-related vision issues.

Product overview

NeoVista Inc operates a science-based vision health information and tools platform. The offering consists of three free interactive browser-based tools: the Online Snellen Chart for visual acuity self-testing, the Color Blind Test using Ishihara-style plates for color vision screening, and the Screen Time Calculator for digital eye strain risk assessment. These tools are complemented by a library of 16+ evidence-based articles covering topics such as computer vision syndrome, blue light filtering, dry eye management, eye drops, monitor settings, desk ergonomics, eye exercises, dietary recommendations for eye health, and corrective lens guidance. The platform is a single unified site (neovistainc.com) with no separate product tiers, modules, or add-ons.

Differentiator

Problem solved

Functional benefit

Products and services

• Online Snellen Chart A free, browser-based visual acuity self-screening tool that displays Snellen chart rows of letters calibrated for standard monitor distances via credit-card scaling. Designed for individual screen workers and general consumers to perform a rough vision check between annual eye appointments.
• Color Blind Test A free online screening tool that uses SVG-rendered Ishihara-style dot plates to detect protan (red-weak), deutan (green-weak), and tritan (blue-yellow) color vision deficiencies in roughly two minutes. Targeted at individual consumers seeking a quick color-vision self-check.
• Screen Time Calculator A free interactive risk-assessment tool that aggregates daily, weekly, and yearly screen time across work computers, phones, tablets, and TV, factoring in break habits, age, and vision correction status to estimate digital eye strain risk levels and blink-deficit. Designed for individual screen workers and parents tracking cumulative exposure.

Quantifiable outcome

• 75% reduction in headaches after implementing 20-20-20 rule with deliberate blinking and standing breaks over 3 weeks
• +4 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators1 record

Recent moves6 records

Others

• Warby Parker: Direct-to-consumer eyewear retailer with significant in-house educational content on eye health, blue light, screen-related vision issues and lens selection. Operates at the same intersection of consumer optical-goods content and tools where NeoVista sits, but with a much larger commercial engine attached.
• Prevent Blindness: Non-profit offering free vision-screening tools and educational content on eye-health topics. Comparable on the free-screening and education pillars, though organized as a non-profit advocacy body rather than a commercial content platform.
• The Vision Council: Optical industry trade association producing consumer-facing research, education and tools (blue-light guidance, eye-health tips). Comparable as a free, well-resourced eye-health information source with industry backing that competes for the same audience.

Direct peers

• EyeQue: Personal vision-testing hardware and app-based tools that let consumers self-screen visual acuity and refractive error at home. Directly comparable because both companies are bringing clinical-grade eye-health screening out of the clinic and onto consumer devices, with an emphasis on actionable personal results.
• All About Vision: Long-established consumer eye-health information site covering eyewear, common conditions and basic screening tools, founded by optometrists. Closest direct peer given the shared mission of evidence-based eye-health content for general consumers and a comparable freemium, content-led model.

Broad incumbents

• CooperVision: Major contact lens manufacturer with a comprehensive consumer-education section on eye health, screen use and lens selection. Comparable as a supplier-side incumbent publishing consumer eye-health content, with an order-of-magnitude larger marketing budget and clinical resources.
• Bausch + Lomb: Major ophthalmic pharmaceutical and consumer-products company with an extensive consumer-educational portal on eye conditions, supplements (AREDS2) and eyewear. Comparable incumbent with a broader portfolio, stronger distribution, and direct ties to several topics NeoVista's content covers.
• Alcon: Global ophthalmic products and devices company maintaining consumer-facing educational content on vision conditions and treatments. Comparable as a vertically integrated incumbent in the ophthalmology space from which NeoVista originally originated.
• WebMD Eye Health Center: Major consumer health information platform with a dedicated eye-health section covering conditions, treatments and screening advice. Represents the broad-incumbent alternative with materially higher SEO authority and physician-reviewed content depth.
• American Academy of Ophthalmology (EyeSmart): Authoritative ophthalmology-body site providing physician-reviewed patient education on eye diseases and treatments, including consumer screening tools. Significantly higher clinical credibility, SEO weight and traffic than NeoVista, and a closer fit to the heritage of the original NeoVista mission.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds11 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NeoVista